Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases

Virchows Archiv

Volumn 456, Issue 5, 2010, Pages 483-490

  Choschzick, Matthias ^a   Woelber, Linn ^a   Hess, Stephan ^a   Eulenburg, Christine Zu ^a   Schwarz, Jörg ^a,b   Simon, Ronald ^a   Mahner, Sven ^a   Jaenicke, Fritz ^a   Müller, Volkmar ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Trauma and Reconstructive Surgery   (Germany)

Author keywords

Carbonic anhydrase; Metastasis; Prognosis; Vulvar cancer

Indexed keywords

CARBONATE DEHYDRATASE IX; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL METASTASIS; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGIONAL METASTASIS; SCORING SYSTEM; SURVIVAL TIME; TISSUE MICROARRAY; VULVA CARCINOMA; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; VULVA; VULVA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; VULVA; VULVAR NEOPLASMS;

EID: 77952484783     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0905-9     Document Type: Article

References (39)

1. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033
2. Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18:330-337
3. Potter CP, Harris AL (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89:2-7
4. Winum JY, Poulsen SA, Supuran CT (2009) Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 29:419-435
5. Zavada J, Zavadova Z, Pastorekova S et al (1993) Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54:268-274
6. Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164-167
7. Robertson N, Potter C, Harris AL (2004) Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64:6160-6165
8. Kaluz S, Kaluzova M, Liao SY et al (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795:162-172
9. Ivanov S, Liao SY, Ivanova A et al (2001) Expression of hypoxiainducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919
10. Hussain SA, Ganesan R, Reynolds G et al (2007) Hypoxiaregulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 96:104-109
11. Klatte T, Seligson DB, Rao JY (2009) Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 115:1448-1458
12. Loncaster JA, Harris AL, Davidson SE et al (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394-6399
13. Swinson DE, Jones JL, Richardson D (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21:473-482
14. Simon R, Mirlacher M, Sauter G (2004) Tissue microarrays. Biotechniques 36:98-105
15. Petersen I, Schewe C, Schluns K et al (2007) Inter-laboratory validation of PCR-based HPV detection in pathology specimens. Virchows Arch 451:701-716
16. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
17. Woelber L, Mahner S, Voelker K et al (2009) Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res 29:545-552
18. Lee WY, Huang SC, Hsu KF et al (2008) Roles for hypoxiaregulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecol Oncol 108:377-384
19. Choi SW, Kim JY, Park JY et al (2008) Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol 39:1317-1322
20. Tanaka N, Kato H, Inose T et al (2008) Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 99:1468-1475
21. Bubendorf L, Nocito A, Moch H et al (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for highthroughput in situ studies. J Pathol 195:72-79
22. Ruiz C, Seibt S, Al Kuraya K (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118:2190-2194
23. Torhorst J, Bucher C, Kononen J et al (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249-2256
24. Fons G, Hasibuan SM, van der Velden J et al (2007) Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol 60:500-503
25. Gulmann C, Butler D, Kay E et al (2003) Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 42:70-76
26. Rubin MA, Dunn R, Strawderman M et al (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312-319
27. Fons G, van der Velden J, Burger M et al (2009) Validation of tissue microarray technology in vulvar cancer. Int J Gynecol Pathol 28:76-82
28. Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107:1053-1062
29. Kaluz S, Kaluzova M, Chrastina A et al (2002) Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res 62:4469-4477
30. Kopacek J, Barathova M, Dequiedt F et al (2005) MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase I.X. Biochim Biophys Acta 1729:41-49
31. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705-713
32. Kong CS (2009) The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 74:553-561
33. Resnick M (1996) Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia. Hum Pathol 27:234-239
34. Wykoff CC, Beasley N, Watson PH et al (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158:1011-1019
35. Drew PA, al-Abbadi MA, Orlando CA (1996) Prognostic factors in carcinoma of the vulva: a clinicopathologic and DNA flow cytometric study. Int J Gynecol Pathol 15:235-241
36. Svastova E, Hulikova A, Rafajova M et al (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular p.H. FEBS Lett 577:439-445
37. Swietach P, Patiar S, Supuran CT et al (2009) The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in 3-D tumor-cell growths. J Biol Chem 284:20299-20310
38. Mulders P, Bleumer I, Debruyne F, et al. (2004) Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN) Urologe A 43 Suppl 3:S146-147: 146-147
39. Bauer S, Oosterwijk-Wakka JC, Adrian N et al (2009) Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer 125:115-123